Literature DB >> 34788690

Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis.

Masoud Keikha1, Parvin Askari2, Kiarash Ghazvini1, Mohsen Karbalaei3.   

Abstract

OBJECTIVES: Despite excessive resistance of Helicobacter pylori to clarithromycin among the Iranian population, clarithromycin-based therapy is still prescribed in Iran. Recent studies have shown high rates of H. pylori eradication in patients treated with levofloxacin. The main purpose of this study was to compare the effect of levofloxacin with clarithromycin on the eradication of H. pylori infection in the Iranian population.
METHODS: A comprehensive meta-analysis was done for relevant cohort studies and clinical trials to compare the therapeutic effects of levofloxacin and clarithromycin in the Iranian population. We pooled the data using odds ratio (OR) and corresponding 95% confidence interval (CI) to determine the clinical efficacy of levofloxacin versus clarithromycin to treat H. pylori infection. Heterogeneity and publication bias were also measured for the included studies.
RESULTS: Thirteen studies were included in the quantitative synthesis. The eradication rate was significantly higher in patients receiving levofloxacin compared with clarithromycin (75.2% vs. 66.3%; OR = 1.76, 95% CI 1.40-2.20). Additionally, in the subgroup analyses it was confirmed that the cure rate was relatively higher in levofloxacin-treated cases. However, there was significant heterogeneity and publication bias, thus the results should be interpreted with caution.
CONCLUSION: We found that the success of levofloxacin treatment was significantly higher than clarithromycin. Therefore, it is suggested that clarithromycin-based triple therapy be replaced by levofloxacin-based triple therapy in countries with high resistance to clarithromycin such as Iran. Nevertheless, the findings of this study need to be approved with a larger investigation on the Iranian population.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Clarithromycin; Helicobacter pylori; Infection; Levofloxacin; Treatment

Mesh:

Substances:

Year:  2021        PMID: 34788690     DOI: 10.1016/j.jgar.2021.10.019

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.349


  2 in total

1.  Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.

Authors:  Mohsen Karbalaei; Amin Talebi Bezmin Abadi; Masoud Keikha
Journal:  BMC Infect Dis       Date:  2022-06-25       Impact factor: 3.667

2.  Comment on "Evaluation of antibiotic resistance of Helicobacter pylori bacteria obtained from gastric biopsy samples: A cohort study".

Authors:  Kiarash Ghazvini; Masoud Keikha
Journal:  Ann Med Surg (Lond)       Date:  2022-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.